Sub menu

 

 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

1143 result(s) found, displaying 276 to 300

  • AusPAR: Inclisiran

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Inclisiran

  • AusPAR: Amifampridine

    Australian public assessment report (AusPar)
    New AusPAR for Ruzurgi (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome.

  • AusPAR: Tozinameran

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Tozinameran

  • AusPAR: Forxiga

    Australian public assessment report (AusPar)
    Forxiga (dapagliflozin) has been approved for reducing the risk of progressive decline in kidney function in adults with
    proteinuric chronic kidney disease.

  • AusPAR: Sacituzumab govitecan

    Australian public assessment report (AusPar)
    New AusPAR for Trodelvy (sacituzumab govitecan) for the treatment of breast cancer.

  • AusPAR: lemborexant

    Australian public assessment report (AusPar)
    New AusPAR for Dayvigo (lemborexant) for the treatment of insomnia.

  • AusPAR: Tixagevimab and cilgavimab

    Australian public assessment report (AusPar)
    New AusPAR for EVUSHELD (tixagevimab and cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years older

  • AusPAR: Eptinezumab

    Australian public assessment report (AusPar)
    New AusPAR for Vyepti (eptinezumab) for the preventive treatment of migraine in adults.

  • AusPAR: Elasomeran

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Elasomeran

  • AusPAR: ChAdOx-1-S

    Australian public assessment report (AusPar)
    New AusPAR for Vaxzevria (ChAdOx-1-S) for the prevention of COVID-19 caused by SARS-CoV-2

  • AusPAR: Molnupiravir

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Molnupiravir

  • AusPAR: Tozinameran

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Tozinameran

  • AusPAR: Bevacizumab

    Australian public assessment report (AusPar)
    New AusPAR for Abevmy (bevacizumab) for the treatment of various types of cancers.

  • AusPAR: nirmatrelvir/ritonavir

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for nirmatrelvir/ritonavir

  • AusPAR: Rabies immunoglobulin

    Australian public assessment report (AusPar)
    New AusPAR for KamRAB (rabies immunoglobulin) for the treatment of passive, transient post-exposure prophylaxis of rabies infection.

  • AusPAR: Tocilizumab (rch)

    Australian public assessment report (AusPar)
    New AusPAR for ACTEMRA Tocilizumab (rch) for the treatment of coronavirus disease 2019 (COVID-19).

  • AusPAR: Elasomeran (mRNA-1273)

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Elasomeran (mRNA-1273)

  • AusPAR: Pegvaliase

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Pegvaliase

  • AusPAR: Regdanvimab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Regdanvimab